Oramed Pharmaceuticals (NASDAQ: ORMP) was established in 2006, and has developed a unique proprietary platform technology that allows for the oral delivery of drugs presently administered only via injection.

Oramed has an experienced management team with many years of business and pharmaceutical experience, and is backed by world-class scientific experts.

From the company’s inception, Oramed has successfully tested its technology via various animal and human studies on its two flagship products, an orally ingestible insulin capsule, ORMD-0801, and an oral GLP-1 analog (exenatide) capsule, ORMD-0901.


Board of Directors

Scientific Advisory Board

 This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 887907.